Multiparametric magnetic resonance imaging and positron emission tomography findings in neurodegenerative diseases: Current status and future directions

Abstract

Neurodegenerative diseases (NDDs) are characterized by progressive neuronal loss, leading to dementia and movement disorders. NDDs broadly include Alzheimer’s disease, frontotemporal lobar degeneration, parkinsonian syndromes, and prion diseases. There is an ever-increasing prevalence of mild cognitive impairment and dementia, with an accompanying immense economic impact, prompting efforts aimed at early identification and effective interventions. Neuroimaging is an essential tool for the early diagnosis of NDDs in both clinical and research settings. Structural, functional, and metabolic imaging modalities, including magnetic resonance imaging (MRI) and positron emission tomography (PET), are widely available. They show encouraging results for diagnosis, monitoring, and treatment response evaluation. The current review focuses on the complementary role of various imaging modalities in relation to NDDs, the qualitative and quantitative utility of newer MRI techniques, novel radiopharmaceuticals, and integrated PET/MRI in the setting of NDDs.

Neutrophil-lymphocyte ratio as a risk factor for osteoporotic vertebrae fractures and femoral neck fractures

“…It is another important development in the field of medical imaging. [28] MRI is not only more informative than many other imaging techniques in medical imaging, but also different from existing imaging techniques. The use of MRI to image the internal structure of the human body will lead to a revolutionary medical diagnostic tool.…”

Survey on the Most Current Image Processing Methods in Huntington's Disease Diagnostics and Progression Assessment

“…PET imaging in HD uses radioactive tracers to detect changes at the molecular level that could be used as markers of HD progression and to monitor treatment response in HD gene expression carriers (HDGECs): changes in postsynaptic dopamine receptors, cannabinoid, adenosine and GABA receptors, histamine and serotonin receptors, brain metabolism, microglia activation, phosphodiesterase 10A (PDE10A) [85] supported by plasma cytokines (small molecule p75NTR prototype of the ligand LM11A-31) [74]. PET with the use of phosphodiesterase 10A tracer enables detecting changes in preHD up to 25 [55] or even 43 [85] years before clinical symptoms or even before the occurrence of white and grey matter changes [78].…”

Saturation Transfer MRI for Detection of Metabolic and Microstructural Impairments Underlying Neurodegeneration in Alzheimer’s Disease

“…Glucose consumption is strongly associated with synaptic function [ 174 ], with oxidative metabolism in neurons and aerobic glycolysis in astrocytes [ 166 ]. Hypometabolism is a crucial diagnostic target in dementias, reflecting abnormalities of inter- and intra-cellular signaling [ 165 ], synaptic loss [ 34 ], mitochondrial damage [ 175 ], deficiencies in neurotransmitter systems [ 139 , 176 ], and interregional metabolic route disruptions [ 28 , 177 ], which takes place before evident neuronal loss and cerebral atrophy [ 177 ]. Compromised energy metabolism as a hallmark of neurodegeneration allows for differential diagnoses based on which brain regions are affected by impaired glucose consumption [ 173 ].…”